Ticker

Analyst Price Targets — ASO

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
June 11, 2026 9:18 amBarclays$50.00$49.88TheFly Academy Sports price target lowered to $50 from $55 at Barclays
June 10, 2026 12:10 pmUBS$55.00$49.50TheFly Academy Sports price target lowered to $55 from $56 at UBS
June 10, 2026 9:59 amIke BoruchowWells Fargo$50.00$50.37StreetInsider Academy Sports & Outdoors Inc. (ASO) PT Lowered to $50 at Wells Fargo
June 10, 2026 9:19 amKate McShaneGoldman Sachs$60.00$50.37StreetInsider Academy Sports & Outdoors Inc. (ASO) PT Lowered to $60 at Goldman Sachs, 'we have raised our FY26 EPS estimate by ~4%'
May 13, 2026 8:10 pmStephens$78.00$49.97TheFly Academy Sports initiated with an Overweight at Stephens
April 20, 2026 3:47 pmTruist Financial$54.00$57.78TheFly Academy Sports price target raised to $54 from $52 at Truist
April 8, 2026 10:53 amGuggenheim$65.00$56.20TheFly Academy Sports price target raised to $65 from $60 at Guggenheim
March 17, 2026 8:45 pmJoseph CivelloTruist Financial$52.00$49.90StreetInsider Academy Sports & Outdoors Inc. (ASO) PT Lowered to $52 at Truist Securities
March 17, 2026 7:12 pmJonathan MatuszewskiJefferies$61.00$49.90StreetInsider Academy Sports (ASO) PT Lowered to $61 at Jefferies, but 'believe the stock is poised to move higher'
January 15, 2026 1:21 pmMorgan Stanley$55.00$56.28TheFly Academy Sports price target raised to $55 from $52 at Morgan Stanley

Latest News for ASO

Academy Sports + Outdoors Continues Partnership with Boys & Girls Clubs of America to Broaden its Positive Impact

Engagement sustains momentum through programming, events, and donations KATY, Texas, June 23, 2026 /PRNewswire/ -- Academy Sports + Outdoors ("Academy") (Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, today announced the extension of its national partnership with Boys & Girls Clubs of America, reinforcing its focus on making a broad positive impact as well as deepening its…

PRNewsWire • Jun 23, 2026
Trace Neuroscience Initiates Global Clinical Development Program for TRCN-1023, an Antisense Oligonucleotide Designed to Restore UNC13A Function for the Treatment of ALS

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today announced the initiation of its global clinical development program for TRCN-1023, an investigational antisense oligonucleotide (ASO) designed to restore UNC13A protein function for the treatment of amyotrophic lateral…

Business Wire • Jun 22, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ASO.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top